- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04289558
Nitrite Infusion in Children With Malaria
Safety, Feasibility, and Endothelial Effects of Sodium Nitrite Infusion in Children With Falciparum Malaria
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase I, open-label, dose-escalation study that will enroll up to 24 patients total, using a 3+3 dose escalation design, with 3 to 6 patients per dose level at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). At each dose level patients with moderately severe malaria will receive a single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride. Blood pressure and methemoglobin levels will be closely monitored during the infusion and for 24 hours post infusion.
This study will allow a preliminary analysis of the safety of intravenous sodium nitrite in children with moderately severe malaria and is expected to provide preliminary data on its effects on endothelial function. The hypothesis is that sodium nitrite infusion will be safe at low dosage levels. Additionally, since deficiency of nitric oxide is linked to endothelial dysfunction in malaria, there is the hypothesis that sodium nitrite will result in improved markers of endothelial function.
Children are the largest group affected by falciparum malaria. The study population will be male children residing in Tanzania, ages 4-10 years old diagnosed with moderately severe malaria, who have been hospitalized for treatment of their malaria at Hubert Kairuki Medical University in Dar es Salaam, Tanzania. Patients will receive standard anti-malaria and supportive care treatment. The study will enroll up to 24 subjects.
Participants will receive a single intravenous infusion of sodium nitrite diluted in 0.9% sodium chloride. The infusion will be administered over 60 minutes with an infusion pump. Escala-ting doses of sodium nitrite will be administered to patients in 4 dose level cohorts. Patients will be sequentially enrolled starting at the lowest dose level. Individual patients at the same dose level will also be enrolled sequentially, such that the next patient will not receive treatment until completion of a 24- hour safety monitoring period for the prior patient. Dose assign-ment will be based on the order of study enrollment. The maximum tolerated dose (MTD) is the highest dose level wherein ≤ 1 of 6 evaluable patients experiences dose limiting toxicity (DLT). If the MTD is exceeded at the first dose level, then dosing will cease.
Type d'étude
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Dar es Salaam, Tanzanie
- Hubert Kairuki Memorial University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Provision of signed and dated informed consent from parent or legal guardian
- Males, >4 to 10 years of age
- Body weight > 12 kg
Parasitemia with Plasmodium falciparum including:
- Positive rapid diagnostic test result: AND
- >2,500 parasites/microliter by microscopy
Diagnosis of MSM, as follows:
- Clinical syndrome consistent with malaria associated with documented fever (axillary temperature >38C) or reported history of fever in the past 48 hours with no other cause present; AND
- Exhibiting no WHO warning signs or criteria for SM [27]
- A negative G6PD deficiency test (careSTART G6PD quantitative biosensor)
- Requires inpatient parenteral treatment because of inability to tolerate oral therapy
- Hemoglobin > 8 g/dL (subjects with prior blood transfusion will be eligible).
- Systolic blood pressure > 85 mmHg
- Baseline quantitative methemoglobin measurement less than 2%
- Creatinine less than the upper limit of normal
Exclusion Criteria:
- Female gender
- Diagnosis of severe malaria
- Presence of infection, or mixed infection, with non-falciparum strains of malaria
Signs of severe malaria[27], including 1 or more of the following:
- impaired consciousness (Blantyre coma score <3 in children)
- prostration
- multiple convulsions (>2 within 24 hours)
- acidosis (base deficit >8 mEq/L or bicarbonate <15 mmol/L or lactate > 5 mmol/L)
- hypoglycemia (blood glucose < 40 mg/dL or <2.2 mmol/L)
- severe anemia (Hb < 5g/dL )
- renal impairment (serum creatinine >265 uMol/L or 3 mg/dL; or blood urea >20 mmol/L)
- jaundice (bilirubin >50 umol or 3 mg/dL with parasite count >100000/ µL)
- pulmonary edema (including O2sat <92% with RR >30/min)
- circulatory collapse or shock
- significant bleeding
- hyperparasitemia (>10%)
- Presence of concomitant non-malarial infection
- Known G6PD deficiency
- Known chronic illness including renal, cardiac, pulmonary, epilepsy
- History of a reaction to a substance or medication consisting of dyspnea and cyanosis
- History of trauma or bleeding in the 2 weeks prior to presentation
- Clinical impression of disseminated intravascular coagulation
- Subjects treated with parenteral anti-malarial drugs for more than 12 hours
- Current use of drugs with oxidative potential (e.g., nitrates, dapsone, primaquine); or drugs that cause hypotension.
- Known allergic reactions to sodium nitrite injection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Sodium Nitrite
Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)
|
Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute).
The dose amount will depend on when the participant enters the study
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety as measured by number of subjects with at least one adverse event
Délai: 48 hours post infusion
|
Adverse events will be assessed according to the NIH's Table for Grading the Severity of Adult and Pediatric Adverse Events.
Events will be numerically graded 1-5; 1 being a mild event and 5 being death
|
48 hours post infusion
|
Percent change in microvascular function/activation for each of the 4 dosing levels by linear regression
Délai: 48 hours post infusion
|
We will assess possible covariate relationships.
A model will be developed that links the pharmacokinetics with the pharmacodynamic measures of endothelial function and activation
|
48 hours post infusion
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Pro00100364
- R01HL130763 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Paludisme à Falciparum
-
Medicines for Malaria VentureComplétéVolontaires en bonne santé | Malaria Falciparum | Malaria VivaxÉtats-Unis
-
Centers for Disease Control and PreventionNational Institute of Health, PeruComplétéMalaria FalciparumPérou
-
University of OxfordRésiliéPaludisme à P. FalciparumThaïlande
-
National Institute of Allergy and Infectious Diseases...Complété
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteComplétéPaludisme à P. Falciparum | Infection mixte de paludisme à P. FalciparumThaïlande
-
University of OxfordRecrutementPaludisme | Plasmodium falciparumRoyaume-Uni
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami...Complété
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...ComplétéPaludisme à Falciparum non compliquéBengladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...InconnuePaludisme à Falciparum non compliquéBirmanie
-
National Institute of Allergy and Infectious Diseases...Complété
Essais cliniques sur Sodium Nitrite
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleComplété
-
University of DelawareComplétéPression artérielle | Réactivité cérébrovasculaireÉtats-Unis
-
University of DelawareComplété
-
Radboud University Medical CenterInconnueDiabète de type 1 | Ignorance de l'hypoglycémiePays-Bas
-
Austin HealthComplétéSyndrome de réponse inflammatoire systémique | Insuffisance rénale | OligurieAustralie
-
Medical University of GrazComplétéCrise cardiaqueL'Autriche
-
Osaka General Medical CenterComplétéProcédure coronarienne urgenteJapon
-
Erasmus Medical CenterComplétéMaladie rénale chroniquePays-Bas
-
Capital Medical UniversityBeijing Friendship Hospital; Cancer Institute and Hospital, Chinese Academy...InconnueCarcinome du nasopharynxChine